RxDoctor Payments Data

Lawrence Lieberman, MD

Family Medicine · Tulsa, OKNPI 1609859982

Payments from drug & device makers

$1,625in general payments, 2019–2025

Across 119 payments — averaging $13.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$578
  • GSK$287
  • AbbVie$193
  • Dexcom, Inc.$161
  • Amgen$101
  • Boehringer Ingelheim$76
  • plus $230 from 9 others

What the payments were for

  • Food & beverage$1,625100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,625 in reported general payments places this provider in the 70th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$62,063
Medicare patients
160
Services billed
4,361

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate118$114,833
JardianceEmpagliflozin89$113,010
EliquisApixaban110$104,502
OzempicSemaglutide61$87,161
FarxigaDapagliflozin Propanediol85$86,637
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$65,637
XareltoRivaroxaban48$52,647
MyrbetriqMirabegron51$38,357
LinzessLinaclotide58$36,342
Spiriva RespimatTiotropium Bromide51$36,092
EntrestoSacubitril/Valsartan13$26,154
Rosuvastatin Calcium684$24,528
TradjentaLinagliptin22$18,661
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog58$18,302
JanumetSitagliptin Phos/Metformin Hcl43$17,837

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta$76$167,763162 claims
PfizerEliquis$11$104,502110 claims
Novo NordiskOzempic$578$87,16161 claims
GSKTrelegy Ellipta, Breo Ellipta$287$74,88967 claims
Astellas Pharma US IncMyrbetriq$41$38,35751 claims
AbbVieLinzess$193$36,34258 claims
NovartisEntresto$12$26,15413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →